Corvus Pharmaceu Stock Price, News & Analysis

BURLINGAME, Calif., May 25, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 4:00-4:25 pm ET. The presentation will be available via live webcast and accessible for 30 days afterwards through the investor relations section of Corvus' website.

Corvus focuses on developing innovative therapies, with lead candidate mupadolimab in Phase 3 trials for COVID-19 and ongoing studies for T-cell lymphomas. For detailed information, visit www.corvuspharma.com.

Corvus Pharmaceuticals (NASDAQ:CRVS) announced the completion of a $10 million common share sale through its ATM program, with 3,564,228 shares sold to EcoR1 Capital and 35,714 shares to CEO Richard A. Miller at $2.80 per share. The settlement is set for May 6, 2021. This follows an effective shelf registration statement declared on March 19, 2020. Investors are encouraged to review the related prospectus available on the SEC's EDGAR database or by contacting Jefferies LLC directly. The company is focused on advancing its clinical programs, including CPI-006 and CPI-818.

Corvus Pharmaceuticals (Nasdaq: CRVS) provided a business update and reported Q1 2021 financial results. The company is advancing its Phase 3 trial for CPI-006 in hospitalized COVID-19 patients, with full enrollment expected by year-end. Financially, Corvus reported cash and equivalents of $68 million, up from $44.3 million in Q4 2020, aided by a $32 million equity offering. R&D expenses decreased to $8.2 million, while the net loss narrowed to $11.6 million. Corvus is also progressing with CPI-818 and ciforadenant clinical trials, showcasing potential in cancer treatments.

Corvus Pharmaceuticals (CRVS) reported a business update and financial results for Q4 and the full year of 2020. They initiated a Phase 3 study for CPI-006 targeting COVID-19, which showed promising Phase 1 results with no patients requiring mechanical ventilation. Additionally, Corvus co-founded Angel Pharmaceuticals to expedite drug development in China. Financially, they ended 2020 with $44.3 million in cash, down from $78.0 million in 2019 and projected a cash burn of $46-$48 million for 2021. The company reported a net income of $27.1 million for Q4 2020.

BURLINGAME, Calif., March 05, 2021 – Corvus Pharmaceuticals (NASDAQ: CRVS) announced participation in two investor conferences this March. The H.C. Wainwright Global Life Sciences Conference is scheduled for March 9-10, 2021, featuring pre-recorded presentations and one-on-one meetings. A corporate overview by Dr. Richard A. Miller will be available on-demand starting March 9. The 33rd Annual Roth Virtual Conference follows on March 15-17, where Dr. Miller will engage in a fireside chat on March 16 and present additional insights. Webcasts will be accessible through the Corvus website.

Corvus Pharmaceuticals (NASDAQ:CRVS) completed an underwritten public offering of 9,783,660 shares at $3.50 per share, raising gross proceeds of $34.2 million. This includes 1,212,231 shares from underwriters’ partial exercise of their option. The net proceeds for Corvus stand at approximately $31.8 million after expenses. Cantor Fitzgerald & Co. and H.C. Wainwright & Co. are the joint book-running managers for the offering. The shares' offering was made under an effective registration statement with the SEC.

Corvus Pharmaceuticals (NASDAQ:CRVS) has announced the pricing of a public offering of 8,571,429 shares of common stock at $3.50 per share, totaling gross proceeds of $30 million. The offering will support the Phase 3 clinical trial of CPI-006 and the development of other product candidates. Additionally, underwriters have a 30-day option to purchase an extra 1,285,714 shares. The offering is set to close around February 17, 2021, pending customary closing conditions.

Corvus Pharmaceuticals (NASDAQ:CRVS) announced a public offering of its common stock, with all shares being sold by the company. Underwriters may purchase an additional 15% of the shares offered. The company plans to utilize the net proceeds for its Phase 3 clinical trial of CPI-006 and other product developments. The offering is subject to market conditions, and a registration statement for these securities was filed with the SEC.

Corvus Pharmaceuticals (NASDAQ: CRVS) has initiated a Phase 3 clinical trial for CPI-006, targeting hospitalized COVID-19 patients. This randomized, double-blind, placebo-controlled study aims to enroll around 1,000 participants globally, with results expected in Q4 2021. Preliminary Phase 1 results showed promising outcomes, with no patients progressing to mechanical ventilation and a median hospital discharge time of 3.5 days. CPI-006 aims to stimulate B cells for enhanced antibody production, potentially addressing SARS-CoV-2 variants. A separate Phase 2 trial is planned for CPI-818 in T-cell lymphoma.